Aptevo Q2 net loss $7.9M; APVO436 DOR data positive; $5M raise extends cash into 3Q24

Aptevo Therapeutics Inc.

2023-Q2 EPS reported -$0.72

Net loss $7.9M ($1.23/share) vs net income $28.0M in Q2 2022 (which included $37.2M gain); cash $21.0M at June 30.
Closed $5M public equity raise on Aug 4, 2023; warrants could add $10M; cash runway now into Q3 2024.
APVO436 + venetoclax + azacitidine in AML: 82% (9/11) response rate for DOR analysis; 3 patients bridged to transplant.
Phase 2 trials for APVO436 planned: relapsed/refractory in 2H23, frontline in 1H24; ALG.APV-527 Phase 1 interim data in 2H23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.